Search This Blog

Tuesday, April 7, 2026

AC Immune amends Morphomer Tau deal with Eli Lilly

 

AC Immune amends Morphomer Tau deal with Eli Lilly, receives CHF10m upfront and retains eligibility for over CHF1.7b milestones plus royalties

  • Amended agreement introduces an additional Phase 1 development milestone payment under the Morphomer Tau collaboration program.
Posted by at

No comments:

Post a Comment

Note: Only a member of this blog may post a comment.

Subscribe to: Post Comments (Atom)